Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

A single-center random parallel study to compare the efficacy and safety of Mycophenolate mofetil versus intravenous Cyclophosphamide pulses in the treatment of crescentic IgA nephropathy

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing University School of Medicine
• Treatments: Cyclophosphamide; Mycophenolate mofetil; Mycophenolic Acid

Criteria

Inclusion Criteria:

Patient with a diagnosis of IgAN without deposition of C4 and C1q, age 10-70y, sex free

1. Gross hematuria or an active urine sediment

2. Segmental necrotizing lesion of the capillary wall

3. Cellular or fibrocellular crescents ≥ 10%

4. Fibrinoid degeneration of small vessels

5. Fibrin positive Three or more items, with provision of criteria informed consent

Exclusion Criteria:

1. More than four-week treatment with cytotoxic drug, such as CTX, CsA and MMF, prior to enrollment

2. Immune deficiency

3. Serum creatinine ≥ 5.0mg/dl

4. Previous malignancy

5. Pregnancy

6. Hepatitis

7. Diabetic mellitus or obesity

8. Severe infection or CVS complications

9. Henoch-Schonlein purpura nephritis, systemic vasculitis, SLE